Biotechnology’s mind-numbing share price volatility means that only the most risk-tolerant investors should consider owning them — but for investors with a penchant for risk and a stomach tough enough to handle the inevitable pops and drops, there may be opportunities to discover emerging biotech companies with promising pipelines that could send their shares significantly higher in 2015. Ophthotech Corporation […]
US stock market hits milestone following surge in economic growthPublished time: December 23, 2014 22:09Get short URLReuters / Hannibal HanschkeTagsEconomy, Inflation , Interest Rates, Investment, Oil, Real Estate, Retail, USAThe US stock market hit a historic milestone on Tuesday, following an announcement that the country’s economy grew five percent between the months of July and October ‒ its fastest pace […]
Devin Banerjee and David Carey of Bloomberg report,Oil Crash Wipes $11.7 Billion From Buyout Firms’ Holdings:
Oil’s plunge makes energy a great investment for the coming years, according to Blackstone Group LP (BX)’s Stephen Schwarzman and Carlyle (CG) Group LP’s David Rubenstein. For private equity firms, it’s also been painful.More than a dozen firms — including Apollo Global Management LLC (APO), […]
Source: Celgene Corp.The volatility that comes with investing in biotech stocks can test the patience of even the most risk-tolerant investor. Many investors may be better served focusing on companies with proven track records of success rather than concentrating on emerging biotech stocks that are more promise than profit. Fortunately, investing in proven performers doesn’t have to mean sacrificing growth! […]
Forget the Oil Crash – Crush the Market With Biotech StocksAdded by Oliver Wright on December 20, 2014.Saved under MoneyTags: Capitalism, Investing, Monetary PolicyThis post Forget the Oil Crash – Crush the Market With Biotech Stocks appeared first on Daily Reckoning.The financial media is playing the “when will oil bottom?” game to help fill the 24-hour news cycle—but that’s not […]
Alibaba founder Jack Ma celebrates its September IPO at the New York Stock Exchange. (AP Photo/Mark Lennihan)
The IPO market is about to put a bow on its busiest year since 2000, but despite a number of huge successes the figures underlying a banner year show new entrants to the market are facing tougher grading from investors.With 273 U.S. IPOs […]
FundstratTom Lee.See AlsoRBC’s Jon Golub Comes Out With A Bullish 2015 PredictionMORGAN STANLEY: ‘It Ain’t A Bubble Yet’BARCLAYS: Stocks Are Going Nowhere Next Year”Be contrarian,” Tom Lee says. “Investors are expecting 2015 to be a low-return year and are focusing on deflation and Fed tightening.”Lee, the former chief US equity strategist for JPMorgan and current head of Fundstrat Global Advisors, […]
Source: Celgene CorporationThe biotechnology industry has been one of the best performing baskets in the stock market this year, but just because biotech stocks were kind to investors this year doesn’t necessarily mean that they’ll rally next year, too.Biotech stocks can move significantly higher or lower in any given year due to investor’s reaction to data from ongoing drug trials, […]
More Charts
More and more Wall Street strategists* argue we should think about stocks as being in the middle phase of a long-term, multiyear, secular bull market.”Our view, which we have held since the market bottomed in 2009, is that the current bull market is secular, not cyclical,” Charles Schwab’s Liz Ann Sonders said. “Secular bull markets — like from 1949 […]
Biotechnology stocks have been among the market’s top performers this year, with the iShares Nasdaq Biotechnology ETF’s 36% gain handily outpacing the S&P 500 ‘s 14% return. That heady return, however, comes with one potential drawback: It might be tough to figure out which biotech stocks will continue climbing next year. With that in mind, here are three large-cap biotech […]
